

Pieter Gillard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1969832/publications.pdf>

Version: 2024-02-01

85
papers

2,976
citations

257450

24
h-index

175258

52
g-index

86
all docs

86
docs citations

86
times ranked

3439
citing authors

#	ARTICLE	IF	CITATIONS
1	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019, 393, 1937-1947.	13.7	408
2	Sustained function of alginate-encapsulated human islet cell implants in the peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient. <i>Diabetologia</i> , 2013, 56, 1605-1614.	6.3	190
3	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the T1D-GLIM 1). <i>Diabetologia</i> , 2020, 63, 2501-2508.	8.6	190
4	Cellular Islet Autoimmunity Associates with Clinical Outcome of Islet Cell Transplantation. <i>PLoS ONE</i> , 2008, 3, e2435.	2.5	172
5	Insulin analogues in type 1 diabetes mellitus: getting better all the time. <i>Nature Reviews Endocrinology</i> , 2017, 13, 385-399.	9.6	170
6	Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 17444-17449.	7.1	166
7	Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study. <i>Diabetes Care</i> , 2020, 43, 389-397.	8.6	163
8	Effect of Continuous Glucose Monitoring on Glycemic Control, Acute Admissions, and Quality of Life: A Real-World Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1224-1232.	3.6	125
9	Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA). <i>Diabetologia</i> , 2020, 63, 2501-2508.	6.3	102
10	Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 2275-2283.	13.7	100
11	Differences in Baseline Lymphocyte Counts and Autoreactivity Are Associated With Differences in Outcome of Islet Cell Transplantation in Type 1 Diabetic Patients. <i>Diabetes</i> , 2009, 58, 2267-2276.	0.6	96
12	Allograft-Specific Cytokine Profiles Associate with Clinical Outcome After Islet Cell Transplantation. <i>American Journal of Transplantation</i> , 2009, 9, 382-388.	4.7	68
13	Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA). <i>Diabetologia</i> , 2020, 63, 2501-2508.	2.9	46
14	Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 845-854.	11.4	46
15	Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation. <i>Clinical and Experimental Immunology</i> , 2009, 156, 141-148.	2.6	41
16	Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients. <i>Clinical and Experimental Immunology</i> , 2012, 171, 82-90.	2.6	41
17	Relationship Between Time in Range, Glycemic Variability, HbA1c, and Complications in Adults With Type 1 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e570-e581.	3.6	39
18	Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus. <i>Transplantation Reviews</i> , 2017, 31, 69-77.	2.9	37

#	ARTICLE	IF	CITATIONS
19	Comparative Evaluation of Simple Indices of Graft Function After Islet Transplantation. <i>Transplantation</i> , 2011, 92, 815-821.	1.0	36
20	Bariatric Surgery Induces Weight Loss but Does Not Improve Glycemic Control in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2014, 37, e173-e174.	8.6	34
21	Comparison of Sirolimus Alone With Sirolimus Plus Tacrolimus in Type 1 Diabetic Recipients of Cultured Islet Cell Grafts. <i>Transplantation</i> , 2008, 85, 256-263.	1.0	33
22	Sustained Impact of Real-time Continuous Glucose Monitoring in Adults With Type 1 Diabetes on Insulin Pump Therapy: Results After the 24-Month RESCUE Study. <i>Diabetes Care</i> , 2020, 43, 3016-3023.	8.6	28
23	A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody oteelixumab in new-onset type 1 diabetes. <i>Diabetologia</i> , 2021, 64, 313-324.	6.3	27
24	Feasibility, Safety, and Efficacy of Percutaneous Transhepatic Injection of β -Cell Grafts. <i>Journal of Vascular and Interventional Radiology</i> , 2005, 16, 1693-1697.	0.5	26
25	Minimal Functional β -Cell Mass in Intraportal Implants That Reduces Glycemic Variability in Type 1 Diabetic Recipients. <i>Diabetes Care</i> , 2013, 36, 3483-3488.	8.6	26
26	Accuracy and precision of flash glucose monitoring sensors inserted into the abdomen and upper thigh compared with the upper arm. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1503-1507.	4.4	25
27	No Evidence of Increased Hospitalization Rate for COVID-19 in Community-Dwelling Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2020, 43, e118-e119.	8.6	24
28	Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients. <i>Diabetologia</i> , 2010, 53, 36-44.	6.3	23
29	Mortality in Individuals Treated With Glucose-Lowering Agents: A Large, Controlled Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 461-469.	3.6	23
30	Immune responses against islet allografts during tapering of immunosuppression – a pilot study in 5 subjects. <i>Clinical and Experimental Immunology</i> , 2012, 169, 190-198.	2.6	22
31	Plasma GAD65, a Marker for Early β -Cell Loss After Intraportal Islet Cell Transplantation in Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2314-2321.	3.6	22
32	<i>HLA-A*24</i> Is an Independent Predictor of 5-Year Progression to Diabetes in Autoantibody-Positive First-Degree Relatives of Type 1 Diabetic Patients. <i>Diabetes</i> , 2013, 62, 1345-1350.	0.6	20
33	Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. <i>Diabetes Care</i> , 2022, 45, e888-e897.	8.6	20
34	Graves Hyperthyroidism After Stopping Immunosuppressive Therapy in Type 1 Diabetic Islet Cell Recipients With Pretransplant TPO Autoantibodies. <i>Diabetes Care</i> , 2009, 32, 1817-1819.	8.6	19
35	Occurrence of Diabetic Nephropathy After Renal Transplantation Despite Intensive Glycemic Control: An Observational Cohort Study. <i>Diabetes Care</i> , 2019, 42, 625-634.	8.6	19
36	Functional β -Cell Mass and Insulin Sensitivity Is Decreased in Insulin-Independent Pancreas-Kidney Recipients. <i>Transplantation</i> , 2009, 87, 402-407.	1.0	18

#	ARTICLE	IF	CITATIONS
37	Ladarixin, an inhibitor of the interleukin-8 receptors <scp>CXCR1</scp> and <scp>CXCR2</scp>, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1840-1849.	4.4	17
38	Î-Cell Transplantation Restores Metabolic Control and Quality of Life in a Patient With Subcutaneous Insulin Resistance. <i>Diabetes Care</i> , 2004, 27, 2243-2244.	8.6	15
39	Cholestatic liver disease in long-term infantile nephropathic cystinosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, e428-31.	2.8	15
40	In antibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A*24 and HLA-B*18, but not HLA-B*39, are predictors of impending diabetes with distinct HLA-DQ interactions. <i>Diabetologia</i> , 2013, 56, 1964-1970.	6.3	15
41	Relationship between glycaemic variability and hyperglycaemic clamp-derived functional variables in (impending) type 1 diabetes. <i>Diabetologia</i> , 2015, 58, 2753-2764.	6.3	15
42	Combined Analysis of GAD65, miR-375, and Unmethylated Insulin DNA Following Islet Transplantation in Patients With T1D. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 451-460.	3.6	15
43	Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio. <i>PLoS ONE</i> , 2016, 11, e0166702.	2.5	14
44	Otelixizumab in the treatment of Type 1 diabetes mellitus. <i>Immunotherapy</i> , 2011, 3, 1303-1316.	2.0	13
45	Artificial Pancreas Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Project. <i>Journal of Diabetes Science and Technology</i> , 2019, 13, 261-267.	2.2	13
46	Arresting type 1 diabetes after diagnosis: GAD is not enough. <i>Lancet, The</i> , 2011, 378, 291-292.	13.7	12
47	Early Alteration of Kidney Function in Nonuremic Type 1 Diabetic Islet Transplant Recipients Under Tacrolimus-Mycophenolate Therapy. <i>Transplantation</i> , 2014, 98, 451-457.	1.0	12
48	Serum Cytokines as Biomarkers in Islet Cell Transplantation for Type 1 Diabetes. <i>PLoS ONE</i> , 2016, 11, e0146649.	2.5	12
49	<i>HLA-A*24</i> Carrier Status and Autoantibody Surges Posttransplantation Associate With Poor Functional Outcome in Recipients of an Islet Allograft. <i>Diabetes Care</i> , 2016, 39, 1060-1064.	8.6	11
50	Stem-cell-based Therapies for Improving Islet Transplantation Outcomes in Type 1 Diabetes. <i>Current Diabetes Reviews</i> , 2018, 14, 3-13.	1.3	11
51	Glucose control using fast-acting insulin aspart in a real-world setting: A <scp>1</scp>-year, two-centre study in people with type <scp>1</scp> diabetes using continuous glucose monitoring. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2716-2727.	4.4	11
52	Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetesâ€”DEPICT-2 Study. <i>Diabetes</i> , 2018, 67, 213-OR.	0.6	11
53	Hyperglycemic Clamp and Oral Glucose Tolerance Test for 3-Year Prediction of Clinical Onset in Persistently Autoantibody-Positive Offspring and Siblings of Type 1 Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 551-560.	3.6	10
54	The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2020, 170, 108462.	2.8	10

#	ARTICLE	IF	CITATIONS
55	Diabetes Knowledge and Metabolic Control in Type 1 Diabetes Starting With Continuous Glucose Monitoring: FUTURE-PEAK. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3037-e3048.	3.6	10
56	Function and composition of pancreatic islet cell implants in omentum of type 1 diabetes patients. <i>American Journal of Transplantation</i> , 2022, 22, 927-936.	4.7	10
57	Predictive Factors of Allosensitization After Immunosuppressant Withdrawal in Recipients of Long-Term Cultured Islet Cell Grafts. <i>Transplantation</i> , 2013, 96, 162-169.	1.0	9
58	Intermittently scanned continuous glucose monitoring is associated with high satisfaction but increased HbA1c and weight in well-controlled youth with type 1 diabetes. <i>Pediatric Diabetes</i> , 2020, 21, 1465-1474.	2.9	8
59	Post-transplant lymphoma of the pancreatic allograft in a kidney-pancreas transplant recipient: a misleading presentation. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3306-3310.	0.7	7
60	Insulinitis and lymphoid structures in the islets of Langerhans of a 66-year-old patient with long-standing type 1 diabetes. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 478, 1209-1214.	2.8	6
61	Genetic variation at ERBB3/IKZF4 and sexual dimorphism in epitope spreading in single autoantibody-positive relatives. <i>Diabetologia</i> , 2021, 64, 2511-2516.	6.3	6
62	Cardiometabolic and Kidney Protection in Kidney Transplant Recipients With Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical Trials. <i>Transplantation</i> , 2022, 106, 734-748.	1.0	6
63	Hemoglobin A2-Leuven (Î±2Î²2 143(H21) His>Asp): a novel delta-chain variant potentially interfering in hemoglobin A1c measurement using cation exchange HPLC. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, e161-3.	2.3	5
64	Glucose management for exercise using continuous glucose monitoring: should sex and prandial state be additional considerations? Reply to Yardley JE and Sigal RJ [letter]. <i>Diabetologia</i> , 2021, 64, 935-938.	6.3	4
65	Pancreas Islet Cell-Specific Antibody Detection by ELISA. <i>journal of applied laboratory medicine</i> , The, 2022, 7, 66-74.	1.3	4
66	Diabetic Ketoacidosis After Sodium-Glucose Cotransporter Inhibitor Initiation Under Advanced Hybrid Closed-Loop Therapy in Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 516-519.	4.4	4
67	Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression. <i>Transplantation</i> , 2017, 101, 2218-2227.	1.0	3
68	Delayed Bleeding of the Transplant Duodenum After Simultaneous Kidney-pancreas Transplantation: Case Series. <i>Transplantation</i> , 2020, 104, 184-189.	1.0	3
69	Risk for ketonaemia in type 1 diabetes pregnancies with sensor-augmented pump therapy with predictive low glucose suspend compared with low glucose suspend: a crossover RCT. <i>Diabetologia</i> , 2021, 64, 2725-2730.	6.3	3
70	Immune and cell therapy in type 1 diabetes: too little too late?. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 609-621.	3.1	2
71	Formation of amyloid in encapsulated human pancreatic and human stem cell-generated beta cell implants. <i>American Journal of Transplantation</i> , 2021, 21, 2090-2099.	4.7	2
72	249-OR: A Randomized, Double-Blind Phase 2 Trial of the CXCR1/2 Inhibitor Ladarixin in Adult Patients with New-Onset Type 1 Diabetes. <i>Diabetes</i> , 2020, 69, .	0.6	2

#	ARTICLE	IF	CITATIONS
73	Identification of Donor Origin and Condition of Transplanted Islets in Situ in the Liver of a Type 1 Diabetic Recipient. <i>Cell Transplantation</i> , 2017, 26, 1-9.	2.5	1
74	SLC30A8 polymorphism and BMI complement HLA-A*24 as risk factors for poor graft function in islet allograft recipients. <i>Diabetologia</i> , 2018, 61, 1623-1632.	6.3	1
75	Use of Culture to Reach Metabolically Adequate Beta-cell Dose by Combining Donor Islet Cell Isolates for Transplantation in Type 1 Diabetes Patients. <i>Transplantation</i> , 2020, 104, e295-e302.	1.0	1
76	Use of hyperglycemic clamp to assess pancreatectomy and islet cell autotransplant in patient with heterotaxy syndrome and dorsal pancreas agenesis leading to chronic pancreatitis. <i>American Journal of Transplantation</i> , 2020, 20, 3662-3666.	4.7	1
77	Utility of Islet Cell Preparations From Donor Pancreases After Euthanasia. <i>Cell Transplantation</i> , 2022, 31, 096368972210961.	2.5	1
78	Immune responses against islet allografts during tapering of immunosuppression - A pilot study in 5 subjects. <i>Clinical and Experimental Immunology</i> , 2012, , no-no.	2.6	0
79	Cover Image, Volume 20, Issue 6. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, i-i.	4.4	0
80	Glycaemic control on nutritional support: finding stability in unstable times. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 330-331.	11.4	0
81	Pancreatic Insufficiency and an Absent Gallbladder: Connecting the Dots. <i>Gastroenterology</i> , 2020, 159, e8-e9.	1.3	0
82	726-P: Glucose Control Using Fast-Acting Insulin Aspart in a Real-World Setting: A One-Year Multicenter Study in People with Type 1 Diabetes Using Continuous Glucose Monitoring. <i>Diabetes</i> , 2021, 70, 726-P.	0.6	0
83	189-OR: FIDELIO-DKD Study: Analysis of Effects of Finerenone by Baseline A1C. <i>Diabetes</i> , 2021, 70, .	0.6	0
84	1367-P: Effect of Nationwide Reimbursement of Sensor-Augmented Pump (SAP) Therapy in a Paediatric Type 1 Diabetes (T1D) Population on HbA1c, Hypoglycaemia, and Quality of Life (QoL) According to Age Groups in the RESCUE-Paediatrics Study. <i>Diabetes</i> , 2019, 68, 1367-P.	0.6	0
85	Eilandjestransplantatie: huidige inzichten en toekomstperspectieven. <i>Tijdschrift Voor Geneeskunde</i> , 2004, 60, 597-602.	0.0	0